<DOC>
	<DOCNO>NCT01490047</DOCNO>
	<brief_summary>Assess maximum tolerate dose ( MTD ) dose limit toxicity ( DLT ) recombinant human tumor necrosis factor-α ( rhTNF-α ) give single dose intravenously combination liposomal doxorubicin human subject</brief_summary>
	<brief_title>Single Dose Intravenous rhTNF-α Liposomal Doxorubicin Patients With Advanced Solid Tumors Lymphomas</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<criteria>Patient must diagnose solid tumor malignancy lymphoma indicate Caelyx treatment . Patient refractory line standard therapy include biologics , chemo therapy , least one line therapy patient standard treatment exists . Patient measurable disease ( define least one lesion whose long diameter accurately measure &gt; 1 cm ) . At least 2 week elapse since completion last cycle chemotherapy and/or major surgery patient fully recover previous therapy surgery postsurgical complication . The patient normal cardiac ejection fraction MUGA Echocardiogram . ECOG performance status 2 less . Patient least 18 year age . Patient capable give informed consent . Patient childbearing potential use adequate birth control measure ( e.g. , abstinence , barrier method spermicide ; intrauterine device , implantable injectable contraceptive surgical sterilization ) duration study continue use precaution 12 month receive treatment . Positive pregnancy test know pregnancy . Participation clinical trial Known hypersensitivity active substance excipients ( Albumin ) . Patients expose great 450 mg/m2 doxorubicin Caelyx . Patient creatinine &gt; 1.5 x upper limit normal , chronic renal failure require hemodialysis peritoneal dialysis . Platelet count equal less 50,000/mm3 , Hemoglobin le 9.0 g/dL , ANC le 1,000 /mm3 . Patient Sa02 le 93 % room air . Patient detectable ascites portosystemic hypertension cirrhosis . Patient bilirubin &gt; 2.0 , AST ALT 2.5X upper limit normal , alkaline phosphatase 2.5X upper limit normal . Hypercalcaemia &gt; 12 mg/dl ( 2.99 mmol/l ) . Patients contraindication use vasopressor substance . Patient presence transplant solid organ ( exception corneal transplant &gt; 3 month prior screen ) bone marrow transplant . Patient history significant medical illness deem principal investigator subinvestigators unsuitable trial , example : Significant cardiovascular disease , e.g . congestive heart failure ( New York Heart Association Class II , III IV ) , severe angina pectoris , cardiac arrhythmia , myocardial infarction within 3 month period prior treatment , venous thrombosis , occlusive peripheral arterial disease , recent pulmonary embolism . Severe pulmonary dysfunction . A recent history , active peptic ulcer . Severe ascites . Known hypotension .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>